Showing 1 posts of 1 posts found.
Shire's Fosrenol could have a clinical advantage over rival drug Renagel from Genzyme, according to the results of what is …
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease